All In Biotech

Investigational drug · Phase 2

SPC5004

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "SPC5004"

First trial start

2024

Dec 5, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SPC5004", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hypertension (HTN)
  • NYHA Class III Heart Failure
  • NYHA Class IV Heart Failure
  • Diabete Mellitus

Approved drugs for the same conditions: High blood pressure (hypertension) · Heart failure · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "SPC5004" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Hypertension (HTN)

  • QCZ484Phase 23 trials

    Novartis · Hypertension (HTN), Hypertension, Hypercholesterolaemia

  • of QLS1410Phase 22 trials

    Qilu Pharmaceutical Co., Ltd. · Hypertension (HTN), Uncontrolled Hypertension

  • SPC1001Phase 21 trial

    Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure

  • SPC5002Phase 21 trial

    Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure

  • SPC5003Phase 21 trial

    Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.